IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

Axial involvement is present in approximately 25% of patients with PsA, with enthesitis, inflammatory bowel disease, and ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

Patients with osteoarthritis, but not immune-related arthritis, demonstrate increased odds for developing overactive bladder ...